MR Guided High Intensity Focused Ultrasound for Lumbar Back Pain

Withdrawn before enrolling · Not applicable

Conditions studied: Lumbar Facet Joint Pain

In brief

The primary purpose of this protocol is to assess the ExAblate 2100 MR guided high intensity focused ultrasound device as an intervention for treatment of facetogenic lower back pain.

Key facts

Study ID

NCT02291978

Run by

Stanford University

People needed

0

Starts

2014-10-01

Expected to finish

2020-02-20

Last updated by the study team

2020-02-24

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women > 21 years of age and who are skeletally mature
• Body mass index ≤ 30 kg/m2
• Patients who are able to understand and willing to sign a written informed consent document and able to attend all study visits
• Patients with at least 6 months of chronic lower back pain (LBP) localized to the midline or axial low back, with symptoms attributed to the facet joints on physical examination that have persisted despite conservative therapy. Conservative therapy is defined as systemic pain medications and anti-inflammatory medications, as well as physical therapy, such as massage, heating, hydrotherapy, and strengthening exercises.
• Patients with Numerical Rating Scale worst lumbar back pain score of at least 4 out of 10 over the 24 hours preceding the time of rating.
• Patients must have chronic LBP attributed to facet joints as demonstrated by MRI consistent with at least grade 2 facet joint arthritis, with corresponding abnormal activity at the facet joint on 18F-sodium fluoride PET-CT.
• Patients must have an analgesic response to either prior local anesthetic injection to the facet joint or to radiofrequency ablation of the facet joint, with relapse of pain.
• The targeted facet joint must be deeper than 10 mm from the skin

You may not qualify if…

• Patients with severe lumbar lordosis
• Patients with contraindication for MR imaging such as implanted metallic devices that are not MRI-safe, size limitations, claustrophobia. etc
• Patients with known intolerance or allergy to MR contrast agent (gadolinium chelates) including advanced kidney disease (GFR <30 mL/min/1.73 m2) or on dialysis
• Pregnant and nursing patients will be excluded from the study because of a contraindication to administering MRI contrast agents to these patients
• Patients with known intolerance or allergy to medications used for sedation (midazolam), analgesia (fentanyl), and local and regional anesthesia (lidocaine, bupivacaine, and ropivacaine)
• Patients with evidence of lumbosacral radiculopathy on MRI or physical exam findings, including radicular leg pain, or any neurologic deficit at or below the segmental level of the highest facet to be treated, including subjects with impaired sphincter control
• Patients with pain at another location that
• cannot be distinguished from lumbar back pain
• does not rate at least 2 points less in worst pain score compared to lumbar back pain
• requires the use of analgesics
• Patients with gross spinal instability on imaging
• Patients who have lumbar spinal stabilization hardware in place
• Target is:
• NOT visible by non-contrast MRI, OR
• NOT accessible to ExAblate device
• Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 5 hrs of total table time)
• Patients with acute medical condition (e.g. pneumonia, sepsis) that is expected to hinder them from completing this study
• Patients with unstable cardiac status including:
• Unstable angina pectoris on medication
• Patients with documented myocardial infarction within six months of protocol entry
• Congestive heart failure requiring medication (other than diuretic)
• Patients on anti-arrhythmic drugs
• Patients with severe hypertension (diastolic BP > 100 on medication)
• Patients with severe hematologic, neurologic, or other uncontrolled disease (e.g. platelets < 50,000/microL, INR > 1.5)
• Patients who are taking anti-thrombotic medication

Where it is running

• Stanford University — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.